['rheumatoid arthritis']
['filgotinib', 'placebo to match filgotinib', 'csdmards']

        Key Inclusion Criteria:

          -  Have a diagnosis of RA (2010 American College of Rheumatology [ACR]/European League
             Against Rheumatism [EULAR] criteria for RA), and are ACR functional class I-III.

          -  Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints [SJC66]) and ≥6
             tender joints (from a tender joint count based on 68 joints [TJC68]) at screening and
             Day 1

          -  Ongoing treatment with a stable prescription of 1 or 2 csDMARDs

          -  Have received at least one biologic disease modifying antirheumatic drug (bDMARD) for
             the treatment of RA to which they have had an inadequate response or intolerance

        Key Exclusion Criteria:

          -  Previous treatment with any janus kinase (JAK) inhibitor

        NOTE: Other protocol Inclusion/ Exclusion criteria may apply.
      